Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

How to Play PFE Stock as Pfizer Cuts 300 Jobs

Pfizer is set to cut 330 jobs at its Catania plant as it restructures its business.

Barchart · Oct 12

Tukysa Wins FDA Nod for First-Line HER2-Positive Breast Cancer Maintenance After Trial Showed 8.6-Month Longer Median Disease Control

FDA approves Tukysa with Herceptin and Perjeta as maintenance therapy for metastatic HER2-positive breast cancer. Here is who qualifies and the tradeoffs.

Medical Daily · Oct 8

HRSA Names 10 Drugmakers and 21 Drugs for 340B Rebate Pilot as Hospitals Weigh Options Before January Launch

HRSA approved 10 drugmakers and 21 drugs, including Eliquis and Jardiance, for its 340B rebate pilot starting Jan. 1 as hospitals weigh legal options.

Medical Daily · Oct 5

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.

MarketBeat · Oct 3

Florida Sues Pfizer Over Claims It Hid Myocarditis and Miscarriage Risks as COVID Vaccine Sales Hit $80B

Florida alleges Pfizer and Albert Bourla misled consumers about COVID-19 vaccine risks, pregnancy and transmission while Pfizer rejects the claim

International Business Times UK · Oct 2

Californians Deserve Greater Drug Transparency

California prescription drug transparency efforts face new scrutiny over pharmaceutical marketing, patient advocacy funding, PBM pricing practices and insulin costs.

International Business Times · Sep 28

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

MarketBeat · Sep 23

Read news from The Economist, FT, and more,
with one subscription

Pfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priority

Pfizer India has stated that patient safety and product quality are their top priorities following FDA actions. The Karnataka FDA canceled 16 drug licenses and suspended eight others due to counterfeit drugs. A raid uncovered an illegal operation repacking low-cost medicines as branded drugs, particularly Pfizer products. Pfizer has removed…

The Economic Times · Sep 23

Hair Loss Was Reported Far More Often by Women in Zepbound Trials but New Genetics Covers Only Men

Zepbound's FDA label reports hair loss in 7.1% of women versus 0.5% of men. The newest GLP-1 genetic study looked only at men.

Medical Daily · Sep 14

Ahead of Market: 10 things that will decide stock market action on Wednesday

Indian equities extended their decline on Tuesday, with Sensex falling 555 points and Nifty ending below 23,650. Analysts cited elevated crude prices, Fed rate hike concerns and IPO fund absorption, while technical signals suggested 23,600 as key Nifty support.

The Economic Times · Sep 8

360 One Group CEO Bhagat buys 1.3 lakh shares of Novartis India for Rs 22 cr

Karan Bhagat acquired 1.3 lakh Novartis India shares for nearly Rs 22 crore. His firm Kyrush Investments sold an equal number of shares in the transaction. Novartis India also announced acquiring trademarks from Pfizer for Rs 1,250 crore. Earlier, Novartis AG agreed to sell its stake to a consortium. This…

The Economic Times · Sep 7

Men Genetically Prone to Baldness Carry a 7 Percent Added Hair Loss Risk Tied to GLP-1 Biology

An NYU Langone genetic study links GLP-1 receptor activity to a 7 percent increased risk of male pattern hair loss. What the finding does and does not show.

Medical Daily · Sep 3

3 Stocks for Investors Who Still Believe Cash Is King

As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.

MarketBeat · Aug 31

Teens and Young Adults Who Caught COVID Without Vaccination Had the Highest Recorded Heart Inflammation and Death Rates

A study of nearly 4.1 million people aged 16 to 25 compared heart inflammation and death rates after COVID infection and after Pfizer-BioNTech vaccination.

Medical Daily · Aug 29

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily · Aug 28

Updated COVID Shots Matched to the XFG Variant Reach Pharmacies While Federal Eligibility Guidance Remains Unsettled

FDA approved updated 2026-2027 COVID vaccines targeting XFG. Here is who qualifies, what insurance covers, and what guidance is still missing.

The Guardian - US · Aug 28

FDA approves updated Covid-19 vaccines for dominant XFG variant

Decision allows manufacturers to begin shipping doses, but confusion remains about insurance coverage

Medical Daily · Aug 26

Heart Inflammation Was More Common After COVID Infection Than After Pfizer Vaccination in Four Million Young People

A study of 4.1 million people ages 16 to 25 compared myocarditis after COVID infection with myocarditis after vaccination. Here is what it found.

Barchart · Aug 24

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune · Aug 21

CFO turnover at America's largest companies is on pace to hit 18.3%—the highest since the pandemic

The next generation of CFOs stepping in may be younger and less experienced.

Medical Daily · Aug 21

Australian Data Put the Maternal RSV Vaccine at 78 Percent Effective Against Infant Lung Infection Admissions

A JAMA Pediatrics study of 1,012 hospitalized infants found maternal RSV vaccine effectiveness to be 77.8% against lung infection admissions through six months.

Medical Daily · Aug 17

COVID Vaccination Averted an Estimated 4,307 Deaths in King County During the First Eight Months of Rollout

A King County modeling study estimates COVID vaccination averted 16,607 hospitalizations and 4,307 deaths during the first eight months of rollout.

Medical Daily · Aug 15

Expectant Parents Have Two Ways to Shield a Newborn from RSV Before the Season Opens in the Fall

Two RSV options can protect a newborn this season. Here is the timing, the hospitalization data, and what to ask a pediatrician now.

The Conversation · Aug 6

First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often…

Barchart · Aug 6

MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

The Economic Times · Aug 4

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.